Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L52 (MRPL52) is a nuclear-encoded protein that forms part of the large subunit (39S) of the mitochondrial ribosome, often referred to as the mitoribosome[3][5][7]. It is crucial for mitochondrial protein synthesis, facilitating the translation of mitochondrial-encoded genes necessary for oxidative phosphorylation and energy production[3][5][7]. MRPL52 operates within the mitochondria, contributing to ribosomal structural integrity and the specialized process of mitochondrial translation, but it is not considered a conventional therapeutic target such as a receptor, enzyme, or transporter[1][7]. There are currently no known drugs targeting MRPL52, and no reports of it being a clinical biomarker or of specific safety concerns related to its modulation[5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L52 (MRPL52).